Clinical effectiveness of interventions for treatment-resistant anxiety in older people: A systematic review

Health Technology Assessment

Volumn 18, Issue 50, 2014, Pages 1-62

  Barton, Samantha ^a   Karner, Charlotta ^a   Salih, Fatima ^a   Baldwin, David S ^b   Edwards, Steven J ^a  

^a BMJ Technology Assessment Group ^*  (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERICIAZINE; PERPHENAZINE; PREGABALIN; PROCHLORPERAZINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VENLAFAXINE; ANXIOLYTIC AGENT;

ABDOMINAL PAIN; ANXIETY DISORDER; COGNITIVE THERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; META ANALYSIS; METABOLIC DISORDER; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; AGE; AGED; ANXIETY; DRUG THERAPY; PSYCHOTHERAPY; THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTI-ANXIETY AGENTS; ANXIETY; HUMANS; PSYCHOTHERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84940220548     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18500     Document Type: Review

References (202)

1. Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG. Anxiety disorders in older adults: a comprehensive review. Depress Anxiety 2010;27:190-211. http://dx.doi.org/10.1002/da.20653
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602. http://dx.doi.org/10.1001/archpsyc.62.6.593
3. Wetherell JL, Lenze EJ, Stanley MA. Evidence-based treatment of geriatric anxiety disorders. Psychiatr Clin North Am 2005;28:871-96. http://dx.doi.org/10.1016/j.psc.2005.09.006
4. van Balkom AJ, Beekman AT, de Beurs E, Deeg DJ, van Dyck R, van Tilburg W. Comorbidity of the anxiety disorders in a community-based older population in The Netherlands. Acta Psychiatr Scand 2000;101:37-45. http://dx.doi.org/10.1034/j.1600-0447.2000.101001037.x
5. Cairney J, Corna LM, Veldhuizen S, Herrmann N, Streiner DL. Comorbid depression and anxiety in later life: patterns of association, subjective well-being, and impairment. Am J Geriatr Psychiatry 2008;16:201-8. http://dx.doi.org/10.1097/01.JGP.0000300627.93523.c8
6. Schaub RT, Linden M. Anxiety and anxiety disorders in the old and very old: results from the Berlin Aging Study (BASE). Compr Psychiatry 2000;41(Suppl. 1):48-54. http://dx.doi.org/10.1016/S0010-440X(00)80008-5
7. Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med 2006;166:2109-16. http://dx.doi.org/10.1001/archinte.166.19.2109
8. Lanouette N, Stein M. Advances in the Management of Treatment-Resistant Anxiety Disorders. Psychiatryonline, 2013. URL: http://focus.psychiatryonline.org/article.aspx?articleID=53282 (accessed December 2013).
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Arlington, VA: American Psychiatric Association; 2000.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edn. 2013. Arlington, VA: American Psychiatric Association; 2013.
11. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic criteria for research. WHO, 1993. URL: www.who.int/classifications/icd/en/bluebook.pdf (accessed December 2013).
12. American Psychiatric Association. Highlights of Changes from DSM-IV-TR to DSM-5. American Psychiatry Publishing, 2013. URL: www.dsm5.org/Documents/changes%20from%20dsm-iv-tr% 20to%20dsm-5.pdf (accessed December 2013).
13. Gellis ZD, McCracken SG. Anxiety Disorders among Older Adults (literature review). Council for Social Work Education, 2007. URL: www.cswe.org/File.aspx?id=23504 (accessed December 2013).
14. Carmin CN, Wiegartz PS, Scher C. Anxiety disorders in the elderly. Curr Psychiatry Rep 2000;2:13-19. http://dx.doi.org/10.1007/s11920-000-0036-0
15. Lindesay J. Diagnosis of mental illness in elderly people from ethnic minorities. Adv Psychiatr Treat 1998;4:219-26. http://dx.doi.org/10.1192/apt.4.4.219
16. Hales RE, Hilty DA, Wise MG. A treatment algorithm for the management of anxiety in primary care practice. J Clin Psychiatry 1997;58(Suppl. 3):76-80.
17. Meeks T, Lanouette N, Vahia I, Dawes S, Jeste DV, Lebowitz B. Psychiatric Assessment and Diagnosis in Older Adults. Psychiatryonline, 2009. URL: http://focus.psychiatryonline.org/article.aspx?articleID=52781 (accessed December 2013).
18. Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res 2011;63(Suppl. 11):S467-72. http://dx.doi.org/10.1002/acr.20561
19. Royal College of Psychiatrists. Anxiety, Panic and Phobias. RCPSYCH, 2013. URL: www.rcpsych.ac.uk/healthadvice/problemsdisorders/anxiety,panic,phobias.aspx (accessed December 2013).
20. National Institute of Mental Health. Anxiety Disorders. NIMH, 2009. URL: www.nimh.nih.gov/health/publications/anxiety-disorders/nimhanxiety.pdf (accessed December 2013)
21. Gross C, Hen R. The developmental origins of anxiety. Nat Rev Neurosci 2004;5:545-52. http://dx.doi.org/10.1038/nrn1429
22. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 2009;10:397-409. http://dx.doi.org/10.1038/nrn2647
23. Uno H, Tarara R, Else JG, Suleman MA, Sapolsky RM. Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci 1989;9:1705-11.
24. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008;31:464-8. http://dx.doi.org/10.1016/j.tins.2008.06.006
25. Lenze EJ, Wetherell JL. A lifespan view of anxiety disorders. Dialogues Clin Neurosci 2011;13:381-99.
26. Freitas-Ferrari MC, Hallak JE, Trzesniak C, Filho AS, Machado-de-Sousa JP, Chagas MH, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:565-80. http://dx.doi.org/10.1016/j.pnpbp.2010.02.028
27. Kim MJ, Loucks RA, Palmer AL, Brown AC, Solomon KM, Marchante AN, et al. The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav Brain Res 2011;223:403-10. http://dx.doi.org/10.1016/j.bbr.2011.04.025
28. Bremner JD. Neuroimaging studies in post-traumatic stress disorder. Curr Psychiatry Rep 2002;4:254-63. http://dx.doi.org/10.1007/s11920-996-0044-9
29. Bremner JD, Randall P, Scott TM, Bronen RA, Seibyl JP, Southwick SM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry 1995;152:973-81.
30. Gurvits TV, Shenton ME, Hokama H, Ohta H, Lasko NB, Gilbertson MW, et al. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related posttraumatic stress disorder. Biol Psychiatry 1996;40:1091-9. http://dx.doi.org/10.1016/S0006-3223(96)00229-6
31. Stein MB, Koverola C, Hanna C, Torchia MG, McClarty B. Hippocampal volume in women victimized by childhood sexual abuse. Psychol Med 1997;27:951-9. http://dx.doi.org/10.1017/S0033291797005242
32. Bremner JD. Alterations in brain structure and function associated with post-traumatic stress disorder. Semin Clin Neuropsychiatry 1999;4:249-55.
33. Gilbertson MW, Shenton ME, Ciszewski A, Kasai K, Lasko NB, Orr SP, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci 2002;5:1242-7. http://dx.doi.org/10.1038/nn958
34. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001;158:1568-78. http://dx.doi.org/10.1176/appi.ajp.158.10.1568
35. Pauls DL. The genetics of obsessive compulsive disorder: a review of the evidence. Am J Med Genet C Semin Med Genet 2008;148C:133-9. http://dx.doi.org/10.1002/ajmg.c.30168
36. Barlow DH. Unraveling the mysteries of anxiety and its disorders from the perspective of emotion theory. Am Psychol 2000;55:1247-63. http://dx.doi.org/10.1037/0003-066X.55.11.1247
37. Silove D, Parker G, Hadzi-Pavlovic D, Manicavasagar V, Blaszczynski A. Parental representations of patients with panic disorder and generalised anxiety disorder. Br J Psychiatry 1991;159:835-41. http://dx.doi.org/10.1192/bjp.159.6.835
38. Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry 2006;11:805-14. http://dx.doi.org/10.1038/sj.mp.4001852
39. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006;368:2156-66. http://dx.doi.org/10.1016/S0140-6736(06)69865-6
40. Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry 1996;168:308-13. http://dx.doi.org/10.1192/bjp.168.3.308
41. Tyrer P, Seivewright H, Johnson T. The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med 2004;34:1385-94. http://dx.doi.org/10.1017/S0033291704002569
42. Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJ, ten Have M, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005;62:1249-57. http://dx.doi.org/10.1001/archpsyc.62.11.1249
43. Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, et al. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety 2008;25:467-76. http://dx.doi.org/10.1002/da.20329
44. Regier DA, Rae DS, Narrow WE, Kaelber CT, Schatzberg AF. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry Suppl 1998;34:24-8.
45. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the Price. The Cost of Mental Health Care in England to 2026. Kings Fund, 2008. URL: www.kingsfund.org.uk/sites/files/kf/Paying-the-Price-the-cost-of-mental-health-care-England-2026-McCrone-Dhanasiri-Patel-Knapp-Lawton-Smith-Kings-Fund-May-2008_0.pdf (accessed December 2013).
46. Eaton WW, Kramer M, Anthony JC, Dryman A, Shapiro S, Locke BZ. The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area Program. Acta Psychiatr Scand 1989;79:163-78. http://dx.doi.org/10.1111/j.1600-0447.1989.tb08584.x
47. McManus S, Meltzer H, Brugha T, Bebbington P, Jenkins R. Adult Psychiatric Morbidity in England, 2007. Results of a Household Survey. National Centre for Social Research and the Department of Health Sciences, 2007. URL: www.esds.ac.uk/doc/6379/mrdoc/pdf/6379research_report.pdf (accessed December 2013).
48. National Collaborating Centre for Mental Health. Generalised Anxiety Disorder in Adults. The NICE Guideline on Management In Primary, Secondary and Community Care. NICE, 2011. URL: www.nice.org.uk/nicemedia/live/13314/52667/52667.pdf (accessed December 2013).
49. National Collaborating Centre for Mental Health. Post-Traumatic Stress Disorder. The Management of PTSD in Adults and Children in Primary and Secondary Care. NICE, 2005. URL: www.nice.org.uk/nicemedia/live/10966/29772/29772.pdf (accessed December 2013).
50. National Collaborating Centre for Mental Health. Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder. NICE, 2005. URL: www.nice.org.uk/nicemedia/live/10976/29947/29947.pdf (accessed December 2013).
51. National Collaborating Centre for Mental Health. Social Anxiety Disorder: Recognition, Assessment and Treatment. NICE, 2013. URL: www.nice.org.uk/nicemedia/live/14168/63868/63868.pdf (accessed December 2013).
52. National Institute for Health and Care Excellence. Pathway for Generalised Anxiety Disorder. NICE Pathways, 2013. URL: http://pathways.nice.org.uk/pathways/generalised-anxiety-disorder (accessed December 2013).
53. National Institute for Health and Care Excellence. Pathway for Panic Disorder. NICE Pathways, 2013. URL: http://pathways.nice.org.uk/pathways/panic-disorder/panic-disorder-overview (accessed December 2013).
54. National Institute for Health and Care Excellence. Pathway for Obsessive-Compulsive Disorder and Body Dysmorphic Disorder. NICE Pathways, 2013. URL: http://pathways.nice.org.uk/pathways/obsessive-compulsive-disorder (accessed December 2013).
55. National Institute for Health and Care Excellence. Pathway for Post-Traumatic Stress Disorder. NICE Pathways, 2013. URL: http://pathways.nice.org.uk/pathways/post-traumatic-stress-disorder (accessed December 2013).
56. National Institute for Health and Care Excellence. Pathway for Social Anxiety Disorder. NICE Pathways, 2013. URL: http://pathways.nice.org.uk/pathways/social-anxiety-disorder (accessed December 2013).
57. Lewis C, Pearce J, Bisson JI. Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: systematic review. Br J Psychiatry 2012;200:15-21. http://dx.doi.org/10.1192/bjp.bp.110.084756
58. Rodgers M, Asaria M, Walker S, McMillan D, Lucock M, Harden M, et al. The clinical effectiveness and cost-effectiveness of low-intensity psychological interventions for the secondary prevention of relapse after depression: a systematic review. Health Technol Assess 2012;16(28). http://dx.doi.org/10.3310/hta16280
59. National Health Service. Improving Access to Psychological Therapies. 2007. URL: www.iapt.nhs.uk/ (accessed December 2013).
60. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 2013. URL: www.bnf.org/bnf/index.htm (accessed December 2013).
61. Thorp SR, Ayers CR, Nuevo R, Stoddard JA, Sorrell JT, Wetherell JL. Meta-analysis comparing different behavioral treatments for late-life anxiety. Am J Geriatr Psychiatry 2009;17:105-15. http://dx.doi.org/10.1097/JGP.0b013e31818b3f7e
62. Rochon PA. Drug Prescribing for Older Adults. UpToDate, 2013. URL: www.uptodate.com/contents/drug-prescribing-for-older-adults (accessed December 2013).
63. Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev 2006;4:CD005473.
64. Gale C, Millichamp J. Generalised Anxiety Disorder. Clinical Evidence, 2011. URL: http://clinicalevidence.bmj.com/x/systematic-review/1002/interventions.html (accessed December 2013).
65. Kumar S, Malone D. Panic Disorder. Clinical Evidence, 2008. URL: http://clinicalevidence.bmj.com/x/systematic-review/1010/interventions.html (accessed December 2013).
66. Bisson JI. Post-Traumatic Stress Disorder. Clinical Evidence, 2009. URL: http://clinicalevidence.bmj.com/x/systematic-review/1005/interventions.html (accessed December 2013).
67. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat 2012;8:203-15. http://dx.doi.org/10.2147/NDT.S23317
68. Soomro GM. Obsessive Compulsive Disorder. Clinical Evidence, 2011. URL: http://clinicalevidence. bmj.com/x/systematic-review/1004/interventions.html (accessed December 2013).
69. Older People's Psychological Therapies Working Group. The Challenge of Delivering Psychological Therapies for Older People in Scotland. 2011. URL: www.scotland.gov.uk/Resource/0039/00392671.pdf (accessed December 2013).
70. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-96. http://dx.doi.org/10.1177/0269881105059253
71. Baldwin D, Rudge S. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol 1995;9(Suppl. 4):41-5. http://dx.doi.org/10.1097/00004850-199501004-00006
72. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001;3:22-7. http://dx.doi.org/10.4088/PCC.v03n0105
73. De Wilde S, Carey IM, Harris T, Richards N, Victor C, Hilton SR, et al. Trends in potentially inappropriate prescribing amongst older UK primary care patients. Pharmacoepidemiol Drug Saf 2007;16:658-67. http://dx.doi.org/10.1002/pds.1306
74. Berger M, Roth B. Pharmacology of serotonergic and central adrenergic neurotransmission. In Golan D, Tashjian A, Armstrong E, Armstrong A, editors. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 3rd edn. Philadelphia, PA: Lippincott, Williams & Wilkins; 2011. pp. 207-24.
75. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551. http://dx.doi.org/10.1136/bmj.d4551
76. Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med 2012;157:498-511. http://dx.doi.org/10.7326/0003-4819-157-7-201210020-00525
77. Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther 2009;31:1345-59. http://dx.doi.org/10.1016/j.clinthera.2009.07.004
78. Edwards S, Hamilton V, Nherera L, Trevor N. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol Assess 2013;17(54). http://dx.doi.org/10.3310/hta17540
79. Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 2007;3:185-91. http://dx.doi.org/10.2147/nedt.2007.3.2.185
80. Eison AS, Temple DL Jr., Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986;80:1-9. http://dx.doi.org/10.1016/0002-9343(86)90325-6
81. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2005;66:353-9. http://dx.doi.org/10.4088/JCP.v66n0312
82. Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA 2011;306:493-502. http://dx.doi.org/10.1001/jama.2011.1080
83. Sachdev PS, Loo CK, Mitchell PB, McFarquhar TF, Malhi GS. Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol Med 2007;37:1645-9. http://dx.doi.org/10.1017/S0033291707001092
84. Storch EAG. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry 2013;74: e527-32. http://dx.doi.org/10.4088/JCP.12m08278
85. Zhang ZJ, Wang XY, Tan QR, Jin GX, Yao SM. Electroacupuncture for refractory obsessive-compulsive disorder: a pilot waitlist-controlled trial. J Nerv Ment Dis 2009;197:619-22. http://dx.doi.org/10.1097/NMD.0b013e3181b05fd1
86. Hoertel N, Le Strat Y, Blanco C, Lavaud P, Dubertret C. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety 2012;29:614-20. http://dx.doi.org/10.1002/da.21937
87. Centre for Reviews and Dissemination. CRD's Guidance for Undertaking Reviews in Healthcare. 2011. URL: www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm (accessed December 2013).
88. Centre for Reviews and Dissemination. Clinical Effectiveness of Interventions for Treatment-Resistant Anxiety in Older People: a Systematic Review (PROSPERO record). University of York, 2013. URL: www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013005612 (accessed December 2013).
89. Information Specialists' Sub-Group. The InterTASC Information Specialists' Sub-Group Search Filter Resource. 2013. URL: https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/methods-of-developing-search-filters (accessed December 2013).
90. Scottish Intercollegiate Guidelines Network. Search Filters. SIGN, 2013. URL: www.sign.ac.uk/methodology/filters.html (accessed December 2013).
91. Clinical Evidence. Study Design Search Filters. 2013. URL: http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665076.html (accessed December 2013).
92. University of Texas (School of Public Health). Search Filters for Ovid Medline, Ovid PsycINFO, PubMed, EBSCO CINAHL. 2013. URL: https://sph.uth.edu/charting/Ovid_PsycINFO_filters.htm (accessed December 2013).
93. Nordhus IH, Pallesen S. Psychological treatment of late-life anxiety: an empirical review. J Consult Clin Psychol 2003;71:643-51. http://dx.doi.org/10.1037/0022-006X.71.4.643
94. Pinquart M, Duberstein PR. Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventions. Am J Geriatr Psychiatry 2007;15:639-51. http://dx.doi.org/10.1097/JGP.0b013e31806841c8
95. Ginsberg DL. Ziprasidone for treatment-resistant generalized anxiety disorder. Prim Psychiatry 2005;12:28-9.
96. Wetherell JL, Petkus AJ, Thorp SR, Stein MB, Chavira DA, Campbell-Sills L, et al. Age differences in treatment response to a collaborative care intervention for anxiety disorders. Br J Psychiatry 2013;203:65-72. http://dx.doi.org/10.1192/bjp.bp.112.118547
97. Gould RL, Coulson MC, Howard RJ. Efficacy of cognitive behavioral therapy for anxiety disorders in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc 2012;60:218-29. http://dx.doi.org/10.1111/j.1532-5415.2011.03824.x
98. Voshaar RC. Lack of interventions for anxiety in older people. Br J Psychiatry 2013;203:8-9. http://dx.doi.org/10.1192/bjp.bp.113.127639
99. Bartlam B, Crome P, Lally F, Beswick AD, Cherubini A, Clarfield AM, et al. The views of older people and carers on participation in clinical trials: the PREDICT study. Clin Invest 2012;2:327-36. http://dx.doi.org/10.4155/cli.12.4
100. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 1994; p.435. URL: http://justines2010blog.files.wordpress.com/2011/03/dsm-iv.pdf (last accessed 6 June 2014).
101. Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF, et al. Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry 2005;57:510-16. http://dx.doi.org/10.1016/j.biopsych.2004.11.042
102. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009;29:51-5. http://dx.doi.org/10.1097/JCP.0b013e318192e9a4
103. Allgulander C. Novel approaches to treatment of generalized anxiety disorder. Curr Opin Psychiatry 2010;23:37-42. http://dx.doi.org/10.1097/YCO.0b013e328333d574
104. Altamura AC, Serati M, Buoli M, Dell'Osso B. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol 2011;26:201-5. http://dx.doi.org/10.1097/YIC.0b013e3283457d73
105. Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008;18:455-61. http://dx.doi.org/10.1016/j.euroneuro.2008.01.006
106. Anderson SW, Booker MB Jr., Cognitive behavioral therapy versus psychosurgery for refractory obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2006;18:129. http://dx.doi.org/10.1176/appi.neuropsych.18.1.129
107. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002;17:115-19. http://dx.doi.org/10.1097/00004850-200205000-00004
108. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 1997;154:1293-5.
109. Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005;57:474-9. http://dx.doi.org/10.1016/j.biopsych.2004.11.039
110. Blank S, Lenze EJ, Mulsant BH, Dew MA, Karp JF, Shear MK, et al. Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. J Clin Psychiatry 2006;67:468-72. http://dx.doi.org/10.4088/JCP.v67n0319
111. Blay SL, Marinho V, Blay SL, Marinho V. Anxiety disorders in old age. Curr Opin Psychiatry 2012;25:462-7. http://dx.doi.org/10.1097/YCO.0b013e3283578cdd
112. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005;66:1321-5. http://dx.doi.org/10.4088/JCP.v66n1016
113. Bresolin N, Monza G, Scarpini E, Scarlato G, Straneo G, Martinazzoli A, et al. Treatment of anxiety with ketazolam in elderly patients. Clin Ther 1988;10:536-42.
114. Bruno AM. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012;26:1456-62. http://dx.doi.org/10.1177/0269881111431751
115. Buchsbaum MS, Hollander E, Pallanti S, Baldini RN, Platholi J, Newmark R, et al. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology 2006;53:157-68. http://dx.doi.org/10.1159/000093342
116. Campanini RF, Schoedl AF, Pupo MC, Costa AC, Krupnick JL, Mello MF, et al. Efficacy of interpersonal therapy-group format adapted to post-traumatic stress disorder: an open-label add-on trial. Depress Anxiety 2010;27:72-7. http://dx.doi.org/10.1002/da.20610
117. Carey PD, Vythilingum B, Seedat S, Muller JE, Ameringen M, Stein DJ. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry 2005;5:5. http://dx.doi.org/10.1186/1471-244X-5-5
118. Carr C, d'Ardenne P, Sloboda A, Scott C, Wang D, Priebe S. Group music therapy for patients with persistent post-traumatic stress disorder: an exploratory randomized controlled trial with mixed methods evaluation. Psychol Psychother 2012;85:179-202. http://dx.doi.org/10.1111/j.2044-8341.2011.02026.x
119. Crocq MA, Leclercq P, Guillon MS, Bailey PE, Crocq MA, Leclercq P, et al. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. Eur Psychiatry 2002;17:296-7. http://dx.doi.org/10.1016/S0924-9338(02)00673-9
120. Csigo K, Harsanyi A, Demeter G, Rajkai C, Nemeth A, Racsmany M. Long-term follow-up of patients with obsessive-compulsive disorder treated by anterior capsulotomy: a neuropsychological study. J Affect Disord 2010;126:198-205. http://dx.doi.org/10.1016/j.jad.2010.02.127
121. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000;10:165-9. http://dx.doi.org/10.1016/S0924-977X(00)00065-1
122. David D, De Faria L, Mellman TA. Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD. Depress Anxiety 2006;23:489-91. http://dx.doi.org/10.1002/da.20187
123. Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004;65:37-43. http://dx.doi.org/10.4088/JCP.v65n0106
124. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010;12:CD008120. http://dx.doi.org/10.1002/14651858.CD008120.pub2
125. Di NM, Tedeschi D, Martinotti G, De VO, Monetta M, Pozzi G, et al. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. J Clin Psychopharmacol 2011;31:675-7. http://dx.doi.org/10.1097/JCP.0b013e31822c29a8
126. Dick PH, Sweeney ML, Crombie IK. Controlled comparison of day-patient and out-patient treatment for persistent anxiety and depression. Br J Psychiatry 1991;158:24-7. http://dx.doi.org/10.1192/bjp.158.1.24
127. Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol 2010;24:297-307. http://dx.doi.org/10.1177/0269881108099423
128. Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol 2011;31:763-8. http://dx.doi.org/10.1097/JCP.0b013e3182367aee
129. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2005;15:69-74. http://dx.doi.org/10.1016/j.euroneuro.2004.04.004
130. Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 1998;55:918-24. http://dx.doi.org/10.1001/archpsyc.55.10.918
131. Fava GA, Savron G, Zielezny M, Grandi S, Rafanelli C, Conti S. Overcoming resistance to exposure in panic disorder with agoraphobia. Acta Psychiatr Scand 1997;95:306-12. http://dx.doi.org/10.1111/j.1600-0447.1997.tb09636.x
132. Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 2005;20:223-6. http://dx.doi.org/10.1097/00004850-200507000-00005
133. Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 2006;21:337-43. http://dx.doi.org/10.1097/01.yic.0000215083.57801.11
134. Geus F, Denys D, Westenberg HG. Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007;22:77-84. http://dx.doi.org/10.1097/YIC.0b013e32801182f7
135. Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, et al. Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol Psychiatry 2010;67:535-42. http://dx.doi.org/10.1016/j.biopsych.2009.11.028
136. Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology 2013;228:633-40. http://dx.doi.org/10.1007/s00213-013-3067-z
137. Hinton DE, Pham T, Tran M, Safren SA, Otto MW, Pollack MH. CBT for Vietnamese refugees with treatment-resistant PTSD and panic attacks: a pilot study. J Traum Stress 2004;17:429-33. http://dx.doi.org/10.1023/B:JOTS.0000048956.03529.fa
138. Hinton DE, Chhean D, Pich V, Safren SA, Hofmann SG, Pollack MH. A randomized controlled trial of cognitive-behavior therapy for Cambodian refugees with treatment-resistant PTSD and panic attacks: a cross-over design. J Trauma Stress 2005;18:617-29. http://dx.doi.org/10.1002/jts.20070
139. Hinton DE, Hofmann SG, Pollack MH, Otto MW. Mechanisms of efficacy of CBT for Cambodian refugees with PTSD: improvement in emotion regulation and orthostatic blood pressure response. CNS Neurosci Ther 2009;15:255-63. http://dx.doi.org/10.1111/j.1755-5949.2009.00100.x
140. Hinton DE, Hofmann SG, Rivera E, Otto MW, Pollack MH. Culturally adapted CBT (CA-CBT) for Latino women with treatment-resistant PTSD: a pilot study comparing CA-CBT to applied muscle relaxation. Behav Res Ther 2011;49:275-80. http://dx.doi.org/10.1016/j.brat.2011.01.005
141. Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20:556-9. http://dx.doi.org/10.1097/00004714-200010000-00011
142. Hoffart A, Due-Madsen J, Lande B, Gude T, Bille H, Torgersen S. Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. J Clin Psychiatry 1993;54:481-7.
143. Hofmann SG, Sawyer AT, Korte KJ, Smits JA. Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int J Cogn Ther 2009;2:160-75. http://dx.doi.org/10.1521/ijct.2009.2.2.160
144. Hollander E, Baldini RN, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003;6:397-401. http://dx.doi.org/10.1017/S1461145703003730
145. Huff W, Lenartz D, Schormann M, Lee S-H, Kuhn J, Koulousakis A, et al. Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: outcomes after one year. Clin Neurol Neurosurg 2010;112:137-43. http://dx.doi.org/10.1016/j.clineuro.2009.11.006
146. Kampman MK. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry 2002;63:772-7. http://dx.doi.org/10.4088/JCP.v63n0904
147. Kang JI, Kim CH, Namkoong K, Lee CI, Kim SJ. A randomized controlled study of sequentially applied repetitive transcranial magnetic stimulation in obsessive-compulsive disorder. J Clin Psychiatry 2009;70:1645-51. http://dx.doi.org/10.4088/JCP.08m04500
148. Katz IRR. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: Pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 2002;50:18-25. http://dx.doi.org/10.1046/j.1532-5415.2002.50003.x
149. Khan A, Atkinson S. Extended release quetiapine fumarate (Quetiapine XR) as adjunct therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study. Psychopharmacol Bull 2011;44.
150. Kolivakis TT, Margolese HC. The pharmacotherapy of treatment-resistant anxiety disorders in adults in the setting of cognitive-behavioral therapy. In Sookman D, Leahy RL, editors. Treatment Resistant Anxiety Disorders. New York, NY: Taylor & Francis; 2010. pp. 323-46.
151. Koran LM, Aboujaoude E, Ward H, Shapira NA, Sallee FR, Gamel N, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2006;26:79-83. http://dx.doi.org/10.1097/01.jcp.0000195112.24769.b3
152. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2009;70:1530-5. http://dx.doi.org/10.4088/JCP.08m04605
153. Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2008;28:550-4. http://dx.doi.org/10.1097/JCP.0b013e318185e735
154. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005;66:736-43. http://dx.doi.org/10.4088/JCP.v66n0610
155. Lippitz BE, Mindus P, Meyerson BA, Kihlstrom L, Lindquist C, Lippitz BE, et al. Lesion topography and outcome after thermocapsulotomy or gamma knife capsulotomy for obsessive-compulsive disorder: relevance of the right hemisphere. Neurosurgery 1999;44:452-8. http://dx.doi.org/10.1097/00006123-199903000-00005
156. Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol 2010;30:185-9. http://dx.doi.org/10.1097/JCP.0b013e3181d21951
157. Macklin ML, Metzger LJ, Lasko NB, Berry NJ, Orr SP, Pitman RK. Five-year follow-up study of eye movement desensitization and reprocessing therapy for combat-related posttraumatic stress disorder. Compr Psychiatry 2000;41:24-7. http://dx.doi.org/10.1016/S0010-440X(00)90127-5
158. Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol 2008;18:364-72. http://dx.doi.org/10.1016/j.euroneuro.2008.01.001
159. Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, et al. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Eng J Med 2008;359:2121-34. http://dx.doi.org/10.1056/NEJMoa0708514
160. Mansur CG, Myczkowki ML, de Barros CS, Sartorelli MC, Bellini BB, Dias AM, et al. Placebo effect after prefrontal magnetic stimulation in the treatment of resistant obsessive-compulsive disorder: a randomized controlled trial. Int J Neuropsychopharmacol 2011;14:1389-97. http://dx.doi.org/10.1017/S1461145711000575
161. Mantovani A, Simpson HB, Fallon BA, Rossi S, Lisanby SH. Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol 2010;13:217-27. http://dx.doi.org/10.1017/S1461145709990435
162. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001;158:1982-8. http://dx.doi.org/10.1176/appi.ajp.158.12.1982
163. Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009;70:863-8. http://dx.doi.org/10.4088/JCP.08m04369
164. Mavissakalian MR. Sertraline in panic disorder: initial treatment versus switch strategy. J Clin Psychopharmacol 2003;23:646-51. http://dx.doi.org/10.1097/01.jcp.0000096248.95165.ac
165. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-84. http://dx.doi.org/10.1097/00004714-199106000-00005
166. McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, Cance-Katz E, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993;150:647-9.
167. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch General Psychiatry 1994;51:302-8. http://dx.doi.org/10.1001/archpsyc.1994.03950040046006
168. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801. http://dx.doi.org/10.1001/archpsyc.57.8.794
169. Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol 2007;27:207-10. http://dx.doi.org/10.1097/01.jcp.0000248620.34541.bc
170. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2011;25:439-52. http://dx.doi.org/10.1177/0269881110378371
171. Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2011;31:174-9. http://dx.doi.org/10.1097/JCP.0b013e31820e3db6
172. Nakatani E, Nakagawa A. Outcome of additional behaviour therapy including treatment discontinuation for fluvoxamine non-responders with obsessive-compulsive disorder. Psychother Psychosom 2008;77:393-4. http://dx.doi.org/10.1159/000151521
173. Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006;67:15-22. http://dx.doi.org/10.4088/JCP.v67n0103
174. Nuttin BJ, Gabriëls LA, Cosyns PR, Meyerson BA, Andréewitch S, Sunaert SG, et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery 2003;52:1263-72. http://dx.doi.org/10.1227/01.NEU.0000064565.49299.9A
175. Okun MS, Mann G, Foote KD, Shapira NA, Bowers D, Springer U, et al. Deep brain stimulation in the internal capsule and nucleus accumbens region: responses observed during active and sham programming. J Neurol Neurosurg Psychiatry 2007;78:310-14. http://dx.doi.org/10.1136/jnnp.2006.095315
176. Osuch EA, Benson BE, Luckenbaugh DA, Geraci M, Post RM, McCann U. Repetitive TMS combined with exposure therapy for PTSD: a preliminary study. J Anxiety Disord 2009;23:54-9. http://dx.doi.org/10.1016/j.janxdis.2008.03.015
177. Oude Voshaar RC, Hendriks GJ, Keijsers G, van Balkom AJ. Cognitive behavioural therapy for anxiety disorders in later life. Cochrane Database Syst Rev 2009;1:CD007674.
178. Peet M, Ali S. Propranolol and atenolol in the treatment of anxiety. Int Clin Psychopharmacol 1986;1:314-19. http://dx.doi.org/10.1097/00004850-198610000-00005
179. Pittenger CK. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol 2008;28:363-7. http://dx.doi.org/10.1097/JCP.0b013e3181727548
180. Pollack MH. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 2001;62(Suppl. 19):20-5.
181. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006;59:211-15. http://dx.doi.org/10.1016/j.biopsych.2005.07.005
182. Prasko J, Pasková B, Záleský R, Novák T, Kopecek M, Bares M, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuro Endocrinol Lett 2006;27:327-32.
183. Prasko J, Záleský R, Bares M, Horácek J, Kopecek M, Novák T, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled study. Neuro Endocrinol Lett 2007;28:33-8.
184. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003;160:371-3. http://dx.doi.org/10.1176/appi.ajp.160.2.371
185. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996;32:677-82.
186. Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol 2012;27:142-50. http://dx.doi.org/10.1097/YIC.0b013e328350b133
187. Sachdev PS, McBride R, Loo CK, Mitchell PB, Malhi GS, Croker VM. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. J Clin Psychiatry 2001;62:981-4. http://dx.doi.org/10.4088/JCP.v62n1211
188. Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety 2012;29:850-4. http://dx.doi.org/10.1002/da.21996
189. Schutters SI, van Megen HJ, Van Veen JF, Schruers KR, Westenberg HG, Schutters SIJ, et al. Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol 2011;26:72-6. http://dx.doi.org/10.1002/hup.1165
190. Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol 2011;26:51-7. http://dx.doi.org/10.1002/hup.1169
191. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004;55:553-5. http://dx.doi.org/10.1016/j.biopsych.2003.11.010
192. Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, Lebeau RT, et al. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry 2008;69:400-5. http://dx.doi.org/10.4088/JCP.v69n0309
193. Simon NM, Connor KM, Lebeau RT, Hoge EA, Worthington JJ, Zhang W, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology 2008;197:675-81. http://dx.doi.org/10.1007/s00213-008-1087-x
194. Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, Lebeau RT, et al. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry 2009;70:1563-70. http://dx.doi.org/10.4088/JCP.08m04485blu
195. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007;17:79-93. http://dx.doi.org/10.1016/j.euroneuro.2006.07.002
196. Stanley MA, Beck JG, Novy DM, Averill PM, Swann AC, Diefenbach GJ, et al. Cognitive-behavioral treatment of late-life generalized anxiety disorder. J Consult Clin Psychol 2003;71:309-12. http://dx.doi.org/10.1037/0022-006X.71.2.309
197. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1725-7. http://dx.doi.org/10.1176/appi.ajp.158.10.1725
198. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159:1777-9. http://dx.doi.org/10.1176/appi.ajp.159.10.1777
199. Tarrier N, Pilgrim H, Sommerfield C, Faragher B, Reynolds M, Graham E, et al. A randomized trial of cognitive therapy and imaginal exposure in the treatment of chronic posttraumatic stress disorder. J Consult Clin Psychol 1999;67:13-18. http://dx.doi.org/10.1037/0022-006X.67.1.13
200. Thorén P, Asberg M, Cronholm B, Jörnestedt L, Träskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-5. http://dx.doi.org/10.1001/archpsyc.1980.01780240079009
201. van Balkom AJ, Emmelkamp PM, Eikelenboom M, Hoogendoorn AW, Smit JH, van OP, et al. Cognitive therapy versus fluvoxamine as a second-step treatment in obsessive-compulsive disorder nonresponsive to first-step behavior therapy. Psychother Psychosom 2012;81:366-74. http://dx.doi.org/10.1159/000339369
202. Wurthmann C, Klieser E, Lehmann E. Differential therapy in generalized anxiety disorders - 30 single-case experiments. Fortschr Neurol Psychiatr 1995;63:303-9. http://dx.doi.org/10.1055/s-2007-996631